日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort

PROMENADE:帕博利珠单抗治疗早期ER低表达/HER2阴性乳腺癌,法国真实世界队列研究

Cherifi, F; Cabel, L; Bousrih, C; Volant, E; Dalenc, F; Mery, B; Auvray Kuentz, M; Mailliez, A; Ladoire, S; de Nonneville, A; Alexandre, M; Benistant, L; Leheurteur, M; Bailleux, C; Debled, M; Frenel, J-S; Loirat, D; Bastien, E; Aussedat, Q; Bidard, F C; Aho, S; Glenet, A; Mourato-Ribeiro, J; Johnson, A; Christy, F; Emile, G

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France

法国ERBB2低表达与ERBB2零表达转移性乳腺癌的治疗及预后比较

de Calbiac, Ombline; Lusque, Amélie; Mailliez, Audrey; Bachelot, Thomas; Uwer, Lionel; Mouret-Reynier, Marie-Ange; Emile, George; Jouannaud, Christelle; Gonçalves, Anthony; Patsouris, Anne; Diéras, Véronique; Leheurteur, Marianne; Petit, Thierry; Cottu, Paul; Ferrero, Jean-Marc; D'Hondt, Véronique; Desmoulins, Isabelle; Mourato-Ribeiro, Joana; Martin, Anne-Laure; Frenel, Jean-Sébastien